IRIS
TOMELLERI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.329
AS - Asia 1.526
NA - Nord America 1.274
SA - Sud America 279
AF - Africa 30
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 3
Totale 5.445
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 1.218
US - Stati Uniti d'America 1.205
SG - Singapore 539
CN - Cina 489
IT - Italia 269
RO - Romania 265
BR - Brasile 233
HK - Hong Kong 201
SE - Svezia 170
VN - Vietnam 130
DE - Germania 118
FR - Francia 81
GB - Regno Unito 62
CA - Canada 46
FI - Finlandia 39
IN - India 30
JP - Giappone 25
PH - Filippine 23
AR - Argentina 22
PL - Polonia 22
BD - Bangladesh 19
NL - Olanda 19
ES - Italia 18
MX - Messico 18
AT - Austria 14
ZA - Sudafrica 11
TR - Turchia 10
ID - Indonesia 9
LT - Lituania 8
EG - Egitto 7
CO - Colombia 6
IQ - Iraq 6
AE - Emirati Arabi Uniti 5
EC - Ecuador 5
IE - Irlanda 5
MK - Macedonia 5
UA - Ucraina 5
UZ - Uzbekistan 5
VE - Venezuela 5
IR - Iran 4
MY - Malesia 4
SA - Arabia Saudita 4
XK - ???statistics.table.value.countryCode.XK??? 4
AU - Australia 3
KE - Kenya 3
KR - Corea 3
KZ - Kazakistan 3
MA - Marocco 3
PY - Paraguay 3
AL - Albania 2
BE - Belgio 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
HR - Croazia 2
IL - Israele 2
NP - Nepal 2
PE - Perù 2
PK - Pakistan 2
TH - Thailandia 2
UY - Uruguay 2
AZ - Azerbaigian 1
BG - Bulgaria 1
BH - Bahrain 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CL - Cile 1
GE - Georgia 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LV - Lettonia 1
MN - Mongolia 1
PR - Porto Rico 1
PS - Palestinian Territory 1
SN - Senegal 1
TG - Togo 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 5.445
Salva come PNG Salva come JPEG
Città #
Singapore 278
Moscow 241
Dallas 202
Ashburn 200
Hong Kong 194
San Jose 120
Shanghai 116
Milan 69
Beijing 68
New York 67
Hefei 63
Munich 59
Lauterbourg 55
Ho Chi Minh City 51
Los Angeles 48
Boardman 38
São Paulo 35
Lawrence 31
Princeton 31
Hanoi 22
Orem 21
Rome 21
Helsinki 20
Nuremberg 19
Warsaw 19
Montreal 18
Tokyo 17
Atlanta 15
Denver 13
Santa Clara 13
Turku 13
Cesano Boscone 12
Council Bluffs 12
London 12
Chicago 11
Brooklyn 10
Chennai 10
Guangzhou 10
Johannesburg 10
Phoenix 10
Poplar 10
Stockholm 10
Makati City 9
Pune 9
Toronto 9
Ankara 8
Manchester 8
Naples 8
Rio de Janeiro 8
Shenzhen 8
Bari 6
City of London 6
Falkenstein 6
Frankfurt am Main 6
Haiphong 6
Lappeenranta 6
Amsterdam 5
Ancona 5
Boston 5
Dublin 5
Florence 5
Genoa 5
Houston 5
Mexico City 5
Querétaro 5
Tashkent 5
Verona 5
Vittoria 5
Wolfhagen 5
Barnet 4
Brasília 4
Cairo 4
Goito 4
Jiaxing 4
Pisa 4
Pristina 4
Quezon City 4
San Francisco 4
Seattle 4
Skopje 4
Taizhou 4
The Dalles 4
Trento 4
Valencia 4
Vienna 4
Zhengzhou 4
Alessandria 3
Annapolis 3
Baie-D'Urfé 3
Bauru 3
Belo Horizonte 3
Brescia 3
Buffalo 3
Cabanatuan City 3
Can Tho 3
Da Nang 3
Formiga 3
Fortaleza 3
Foshan 3
Hải Dương 3
Totale 2.572
Salva come PNG Salva come JPEG
Nome #
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 373
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 166
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 151
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial 141
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 138
Cardiac magnetic resonance findings in acute and post-acute COVID-19 patients with suspected myocarditis 124
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 124
Liquid biopsy of cerebrospinal fluid enabling the detection and therapeutic targeting of the BRAFV600E mutation in a patient with overlapping Erdheim-Chester/Rosai-Dorfman disease 123
A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM) 119
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 112
Cardiovascular involvement in Erdheim-Chester diseases is associated with myocardial fibrosis and atrial dysfunction 112
Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohort 110
Effectiveness and safety of infliximab dose escalation in patients with refractory Takayasu arteritis: A real-life experience from a monocentric cohort 105
Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series 105
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation 102
Drug retention rates of biological agents in adult onset Still's disease 101
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production 99
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis 99
Anakinra for the Treatment of Antisynthetase Syndrome: A Monocentric Case Series and a Systematic Literature Review 98
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 98
Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study 94
Giant cell arteritis: Update on clinical manifestations, diagnosis, and management 94
DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA 94
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience 93
Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease 93
Myocarditis as a manifestation of Erdheim–Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy 92
Impact of Geographic Location on Diagnosis and Initial Management of Takayasu Arteritis: A Tale of Two Cohorts from Italy and India 92
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 90
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 90
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 89
Clinically isolated aortitis successfully treated with methotrexate monotherapy 89
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients 88
Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies 87
An enlightening scan 84
Mechanisms of hematopoietic clonal dominance in VEXAS syndrome 83
LONG-TERM PATHOPHYSIOLOGIC AND PROGNOSTIC EVALUATION OF DIFFERENT DISEASE SUBSETS IN GIANT CELL ARTERITIS 78
VEXAS associated acute disseminated Encephalo-Myelitis (ADEM)-like syndrome: A case report and review of the literature 77
Clinical and dermoscopic description of accelerated nodulosis after tocilizumab treatment for an isolated aortitis with coronary involvement 72
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease 72
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 69
HETEROGENEITY OF CYTOPENIAS IN VEXAS SYNDROME: A SINGLE CENTRE EXPERIENCE 68
The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort 68
Presenting features and outcomes of cranial-limited and large-vessel giant cell arteritis: a retrospective cohort study 64
Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance: Report of Two Cases and Rationale for Its Therapeutic Use 62
Response to: 'Correspondence on Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: A monocentric survey' by Comarmond et al 58
Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: A monocentric survey 57
Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic 57
Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement 56
Efficacy of interleukin-1 blockade with anakinra in the management of post-COVID-19 steroid-dependent multisystem inflammatory syndrome: a case report 53
Potential acceptance of COVID-19 vaccine in rheumatological patients: A monocentric comparative survey 53
Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series 52
Large Vessel Vasculitis Affecting the Aorta and Its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature 52
Failure of first anti-TNF agent in Takayasu’s arteritis: To switch or to swap? 51
Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance 49
Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis 48
Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients 47
Multimodal chorioretinal imaging in erdheim-chester disease 46
Retention rates of different Janus kinase inhibitors in rheumatoid arthritis: experience from a large monocentric cohort 45
Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease 45
One year later: The case of tocilizumab in COVID-19 45
Myocardial infarction in giant cell arteritis: It is all a matter of balance 44
The target on B cells in Systemic Sclerosis: a “midsummer dream” to extinguish inflammation and prevent early disease progression to fibrosis 43
Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply 41
Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease 40
Spontaneous coronary-artery dissection 36
Real-life use of high-dose anakinra in patients with COVID-19 treated with remdesivir 6
Totale 5.606
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.876
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.876
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 0 0 3 2
2021/202264 0 0 23 17 2 4 6 2 4 3 0 3
2022/2023305 75 58 15 3 8 36 29 38 19 10 9 5
2023/2024403 11 30 52 36 34 59 33 44 3 7 15 79
2024/20251.367 100 29 44 39 68 89 408 118 161 103 91 117
2025/20263.431 256 229 258 483 295 106 292 316 1.041 155 0 0
Totale 5.606